Monthly information on share capital and company voting rights

Rhea-AI Summary

Cellectis (CLLS) reported its monthly share capital and voting rights information for Euronext Growth.

As of May 31, 2026, the company had 100,691,658 shares outstanding and a total of 106,134,467 voting rights (ISIN: FR0010425595).

News Market Reaction – CLLS

+1.94% 2.6x vol

3 alerts

+1.94% Session close to close

$222.90M Market Cap

2.6x Rel. Volume

In the Jun 4 session, CLLS gained 1.94%, reflecting a mild positive market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. Trading volume was elevated at 2.6x the daily average, suggesting notable buying interest.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement provides updated transparency on Cellectis’ capital structure, reporting 100,691,6...

Analysis

This announcement provides updated transparency on Cellectis’ capital structure, reporting 100,691,658 shares and 106,134,467 voting rights as of May 31, 2026. It follows earlier monthly disclosures and comes alongside broader context from recent financial reports and regulatory filings. Investors tracking governance and potential future issuances may note the stable share count and the existence of an effective shelf, while focusing on upcoming clinical and financial milestones highlighted in prior updates.

Key Figures

Total shares: 100,691,658 Total voting rights: 106,134,467 Reference date: 05/31/2026

3 metrics

Total shares 100,691,658 Total number of shares in the capital as of 05/31/2026

Total voting rights 106,134,467 Total number of voting rights as of 05/31/2026

Reference date 05/31/2026 Date of share capital and voting rights snapshot

Historical Context

5 past events · Latest: May 20 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 20	AGM scheduling	Neutral	-3.8%	Announcement of June 25, 2026 annual shareholders general meeting in Paris.
May 12	Clinical data plans	Positive	-0.5%	Plans to present new clinical data on lasme-cel and eti-cel at EHA 2026.
May 11	Q1 2026 results	Neutral	-0.5%	Release of first quarter 2026 financial results and operating update.
May 06	Monthly capital update	Neutral	-2.3%	Monthly disclosure of April 30, 2026 share capital and voting rights table.
May 04	Earnings date notice	Neutral	+1.6%	Notification of May 11, 2026 Q1 results release without a conference call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent administrative and scheduling announcements, including prior monthly capital updates and AGM notices, often coincided with modestly negative next-day price moves.

Recent Company History

Over the last few months, Cellectis has combined clinical, financial and corporate housekeeping news. An April–May sequence included earnings timing, a prior monthly share capital statement with 100,611,481 shares and 106,021,715 voting rights, Q1 2026 results, new EHA 2026 clinical data plans, and the upcoming June 25, 2026 general meeting. The current May 31, 2026 capital and voting rights disclosure continues this pattern of regular capital structure transparency alongside broader development and governance updates.

Key Terms

isin code, share capital, voting rights

3 terms

isin code financial

"Listing market: Euronext Growth ISIN code: FR0010425595"

An ISIN code is a unique identifier for a specific financial asset, like a stock or bond, similar to a product's barcode. It helps investors, traders, and banks quickly and accurately find and track that asset across different markets worldwide. This makes buying, selling, and managing investments more organized and reliable.

share capital financial

"Date | Total number of shares in the capital | Total number of voting rights"

Share capital is the total amount of money a company raises by selling pieces of itself, called shares, to investors. It’s like a company’s savings from many owners, which helps fund its growth and operations. This money matters because it shows how much the company has raised from shareholders and how it’s financed its business.

voting rights regulatory

"Total number of shares in the capital | Total number of voting rights"

Voting rights are the ability of shareholders to have a say in important company decisions, like choosing leaders or approving big changes. They matter because they give owners a voice in how the company is run, similar to how voters influence elections, ensuring the company acts in shareholders’ interests.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PARIS, June 03, 2026 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

Date	Total number of shares in the capital	Total number of voting rights
05/31/2026	100,691,658	106,134,467

For further information on Cellectis, please contact:

Media contacts:
Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Investor Relations contact:
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com 

Attachments

• Voting_Rights_PR_May_2026_EN

FAQ

What is the total number of Cellectis (CLLS) shares as of May 31, 2026?

As of May 31, 2026, Cellectis reported 100,691,658 shares outstanding. According to Cellectis, this figure reflects the total number of shares in the company’s capital listed on Euronext Growth under ISIN code FR0010425595.

How many voting rights does Cellectis (CLLS) report as of May 31, 2026?

Cellectis reported 106,134,467 total voting rights as of May 31, 2026. According to Cellectis, this number represents all voting rights attached to its 100,691,658 shares in the company’s share capital at that date.

On which market is Cellectis (CLLS) share capital information reported for May 2026?

The May 2026 share capital information for Cellectis is reported for the Euronext Growth market. According to Cellectis, this update covers its total shares and voting rights under ISIN code FR0010425595 as of May 31, 2026.

What is the ISIN code for Cellectis (CLLS) shares mentioned in the May 31, 2026 update?

The ISIN code for Cellectis shares in the May 31, 2026 update is FR0010425595. According to Cellectis, this code identifies its shares listed on Euronext Growth for which the share and voting rights data were provided.

Why does Cellectis (CLLS) publish monthly information on share capital and voting rights?

Cellectis publishes monthly share and voting rights data to provide transparent capital information to investors. According to Cellectis, the May 31, 2026 update details current totals of 100,691,658 shares and 106,134,467 voting rights on Euronext Growth.